Summary of Ovarian Stimulation in IVF
Ovarian Stimulation in IVF: A Student's Comprehensive Guide
Introduction
Ovarian stimulation drugs and their management are central to assisted reproductive treatments. This guide summarizes clinically relevant drug classes, monitoring decisions, dose‑selection principles, common failure patterns, and practical management steps for laboratory and clinical teams. It excludes physiology and protocol architecture, which are covered elsewhere.
Definition: Ovarian stimulation drugs are exogenous gonadotropins or supporting agents given to recruit and mature multiple follicles for oocyte retrieval in assisted reproduction.
1. Biosimilars in FSH therapy
What are biosimilars?
Definition: Biosimilars are highly similar versions of licensed biologic drugs that have demonstrated no clinically meaningful difference in safety, purity, or potency compared with the originator through comparability studies.
- Common follitropin alfa biosimilars: Bemfola (Gedeon Richter), Ovaleap (Theramex), Afolia/Primapur (Gedeon Richter, limited markets).
- Regulatory approval is based on pharmacokinetic, pharmacodynamic and clinical bridging trials.
- RCT evidence (Strowitzki 2016; Rettenbacher 2015) shows equivalent oocyte yield and ongoing pregnancy rates versus the originator.
- Typical cost advantage: ~20–30% cheaper than originator.
Practical note: For embryologists and clinicians, originator vs biosimilar is generally an administrative distinction; it should not be treated as a diagnostic variable in cycle interpretation.
2. Choosing a starting FSH dose (overview)
Definition: The starting FSH dose is the initial daily dose prescribed to open the recruitment window and drive follicle growth.
Key inputs for dose selection
- AMH band: primary driver of the starting dose range.
- Age and BMI: increase dose for older patients and higher BMI to compensate for lower responsiveness.
- Prior ovarian response: strongest individualized signal once a cycle history exists.
- Typical final daily dose range: 100–300 IU; rare patients may require more due to receptor pharmacodynamics.
AMH-based practical framework (concise)
| AMH (pmol/L) | Reserve | Starting (ESHRE) | Yield-optimised | Expected oocytes |
|---|---|---|---|---|
| > 30 | Very high | 100–125 IU | 200 IU | 16+ |
| 15–30 | Normal/high | 150–225 IU | 225 IU | 9–14 |
| 5–15 | Reduced | 225–300 IU | 300 IU | 5–9 |
| < 5 | Very reduced | 300 IU | 300 IU | ≤ 5 |
- Yield-optimised dosing trades a higher OHSS risk for larger cohort size and is used when freeze‑all is expected.
3. Mid‑cycle adjustments
- Common in practice but evidence is weak.
- Increasing dose mid-cycle: rarely rescues a poor response because recruitment window typically commits follicles by day 5–6.
- Decreasing dose late: narrows cohort but risks losing maturing follicles; may be used to reduce OHSS risk.
Practical tip: Use mid‑cycle dose changes sparingly and with clear goals; they mostly affect clinician behaviour rather than outcomes.
4. LH activity products and indications
Definition: LH activity agents provide luteinising hormone or LH‑like activity to support theca cell androgen production and later follicular events.
| Product | Source | LH content |
|---|---|---|
| Menopur (hMG) | Postmenopausal urine | 75 IU FSH + 75 IU LH activity (mostly hCG) per vial |
| Luveris (rLH) | CHO cells | 75 IU rLH per vial |
| Pergoveris | CHO cells | Combined rFSH + rLH |
- hMG's LH activity is largely hCG, which has a longer half‑life but acts at the LH receptor.
Who benefits from LH activity?
- **Clear indic
Zaregistruj se pro celé shrnutíAlready have an account? Sign in
Ovarian Stimulation Drugs & Management
Klíčové pojmy: Follitropin alfa biosimilars (Bemfola, Ovaleap) are clinically equivalent to originator and ~20–30% cheaper, Choose starting FSH primarily by AMH band, then modify for age and BMI, Typical starting FSH doses range $100$–$300$ IU daily depending on reserve, Mid‑cycle dose increases rarely rescue poor response after day $5$–$6$; use sparingly, LH agents are mandatory in hypogonadotrophic hypogonadism; benefits in other groups are limited, Agonist trigger causes severe luteal insufficiency and often requires freeze‑all or aggressive luteal support, In programmed FET (no CL), systemic progesterone replacement is required; vaginal‑only regimens can be insufficient, Personalised dosing reduces extremes but does not substantially change average cumulative live birth rates, Monitor initial response, growth trajectory, lead follicle size, premature P4 and OHSS markers, Four causes of under‑stimulation: low starting dose, antagonist subtraction, late dose drop, early trigger, Split cohort on mid‑stim is a signature of synchrony failure and is usually correctable by dose or timing changes, Record of product originator vs biosimilar is administrative; it should not drive interpretive lab decisions